Group 1 - The core index, the CESHKB, increased by 2.22% to 9684.5 points with a trading volume of 19.513 billion [1] - The CESHKB index has risen by 21.28% over the past month, 67.37% over the past three months, and 111.44% year-to-date [1] - The index is designed to reflect the overall performance of biotechnology companies listed in Hong Kong, with a base date of December 12, 2014, and a base point of 2000.0 [1] Group 2 - The top ten holdings of the CESHKB index include: - CanSino Biologics (13.85%) - Innovent Biologics (9.49%) - WuXi Biologics (8.72%) - 3SBio (8.71%) - BeiGene (8.39%) - WuXi AppTec (7.03%) - Kintor Pharmaceutical (5.02%) - Zai Lab (4.33%) - Nuo Therapeutics (3.91%) - Kingstar Biotech (3.8%) [1] - The CESHKB index is fully composed of companies listed on the Hong Kong Stock Exchange, with 100% of its holdings in the healthcare sector [2]

Group 1 - The core viewpoint of the news is the performance and holdings of the Huatai Fuhua Medical Active Growth One-Year Holding Mixed Fund A, which has shown significant returns in various time frames [1] - As of June 30, 2025, the fund's total assets amount to 1.922 billion yuan, with a recent net value of 0.8263 yuan, reflecting a growth of 1.04% [1] - The fund has achieved a return of 15.15% over the past month, 63.14% over the past six months, and 66.59% year-to-date, ranking 506 out of 4688, 60 out of 4532, and 84 out of 4490 respectively in its category [1] Group 2 - The top ten stock holdings of the fund account for a total of 61.79%, with significant positions in companies such as Sanofi (10.07%), Innovent Biologics (8.94%), and Kelun-Biotech (8.71%) [1] - The fund was established on August 21, 2020, and is managed by Zheng Lei, who has extensive experience in the medical and healthcare investment sector [2]

Core Viewpoint - BeOne Medicines Ltd. has granted restricted stock units (RSUs) to 375 participants under the 2016 Option and Incentive Plan, totaling 34,361 American Depositary Shares (ADS), equivalent to 446,693 shares, representing approximately 0.03% of the company's total issued shares as of the announcement date [1]. Summary by Relevant Sections Grant Details - Grant Date: August 8, 2025 - Number of Participants: 375 - Total Number of RSUs Granted: 34,361 ADS - Total Number of Related Shares: 446,693 - Grant Price: $288.18 per ADS (approximately HKD 174.02 per ordinary share) [1]. Vesting Schedule - RSUs will vest 25% annually on the last trading day of each month for four years, contingent on the participants maintaining a service relationship with the company [1]. - For four non-senior management participants, RSUs will vest 25% annually on July 31 for four years, also contingent on continued employment [1]. Additional Information - The RSUs granted do not have performance targets and are considered competitive and in line with the company's practices [1]. - After this grant, there are still 59,660,288 shares available for future grants under the 2016 Option and Incentive Plan [1].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 授出受限制股份單位 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。於2025年8月8日， 董事會薪酬委員會根據2016期權及激勵計劃的條款向三百七十五名承授人授出涉 及合共34,361股美國存託股份的受限制股份單位。 2016期權及激勵計劃項下的受限制股份單位 受限制股份單位詳情如下： 1 授出日期： 2025年8月8日 承授人數目： 三百七十五名 已授出受限制股份單位涉及 的相關股份數目： 446,693 受限制股份單位總數（美國 存託股份）: 34,361 因已授出受限制股份單位獲 歸屬而可予獲得的新美國 存託股份總數： 34,361 授出的代價： 零 美國存託股份於授出日期 的收市價： 於2025年8月8日，董事會薪酬委員會根據2016期權及激勵計劃的條款授 ...

Core Viewpoint - BeiGene (06160.HK) announced the grant of a total of 34,361 restricted stock units to 375 grantees under the 2016 option and incentive plan, equivalent to 446,693 shares, representing approximately 0.03% of the company's total issued shares as of the announcement date [1] Summary by Category - **Company Actions** - The board's compensation committee granted restricted stock units to 375 individuals [1] - The total number of restricted stock units granted is 34,361 [1] - **Shareholder Impact** - The granted units correspond to 446,693 shares [1] - This represents about 0.03% of the total issued shares of the company as of the announcement date [1]

Core Viewpoint - BeiGene (06160.HK) announced the grant of restricted stock units to 375 participants under its 2016 option and incentive plan, totaling 34,361 American Depositary Shares, equivalent to 446,693 shares, representing approximately 0.03% of the company's total issued shares as of the announcement date [1] Summary by Category - **Company Actions** - The board's compensation committee granted restricted stock units to 375 participants [1] - The total number of restricted stock units granted is 34,361 [1] - **Shareholder Impact** - The granted units are equivalent to 446,693 shares [1] - This represents about 0.03% of the total issued shares of the company as of the announcement date [1]

智通财经APP讯，百济神州(06160)公布，于2025年8月8日，董事会薪酬委员会根据2016期权及激励计划 的条款向375名承授人授出涉及合共34,361股美国存托股份的受限制股份单位。 ...

Core Viewpoint - BeiGene Limited (06160) announced the grant of restricted stock units involving a total of 34,361 American Depositary Shares to 375 grantees on August 8, 2025, under the terms of the 2016 option and incentive plan [1] Summary by Relevant Categories - **Company Actions** - The company granted a total of 34,361 restricted stock units to 375 individuals [1] - This action is part of the 2016 option and incentive plan [1] - **Future Implications** - The issuance of restricted stock units may align the interests of employees with those of shareholders, potentially enhancing company performance [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 授出受限制股份單位 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。於2025年8月8日， 董事會薪酬委員會根據2016期權及激勵計劃的條款向三百七十五名承授人授出涉 及合共34,361股美國存託股份的受限制股份單位。 2016期權及激勵計劃項下的受限制股份單位 於2025年8月8日，董事會薪酬委員會根據2016期權及激勵計劃的條款授予三百七 十五名承授人合共34,361股美國存託股份受限制股份單位。該等受限制股份單位 相當於446,693股股份，約佔本公告之日公司發行股份總數的0.03%。 授出受限制股份單位詳情 受限制股份單位詳情如下： 1 授出日期： 2025年8月8日 承授人數目： 三百七十五名 已授出受限制股份單位涉及 的相關股份數目： 446,693 受 ...

高盛主要观点如下： 资金流向上 —— 高盛的交易平台买入呈现 1.2 倍净卖出状态。消费和科技板块是平台最活跃的主题(双 向交易并存，但消费股更适合卖出而科技股更宜买入)。消费板块呈现双向流动，餐饮类股遭遇部分抛 售，而普拉达等零售股则买卖交投活跃。科技板块中，持续在硬科技领域获得买单，但对腾讯音乐等冲 高个股转为卖出。网易也获得较大力度买入。医疗保健 / 制药板块更受青睐 —— 翰森制药虽呈双向交 易但买方更占优势。 香港股市创下自五月初以来的最佳单日表现。 从行业板块来看，医疗保健、科技和消费板块领涨 —— 在中国政府宣布对符合条件的个人消费贷款实 施贴息计划后，国内零售商与消费医疗企业的股价应声上扬。医疗板块中，信达生物(+9%)、药明康德 (+6.2%)、翰森制药(+5.4%)涨幅居前。科技板块以腾讯音乐(+15.6%)表现最为亮眼，其财报大幅超出预 期，多家投行同步上调目标价。其他涨幅显著的个股包括阿里巴巴(+6.1%)、哔哩哔哩(+7.4%)，华虹半 导体(+5.9%)等芯片股亦表现强势。能源与电信板块表现滞后，虽维持涨势但明显跑输大盘，部分资金 正轮动至成长股。 智通财经APP获悉，高盛发布研报 ...